Global study aims to uncover best treatments for Immunotherapy-Linked heart condition
NCT ID NCT07633587
First seen Jun 14, 2026 · Last updated Jun 19, 2026 · Updated 1 time
Summary
ATROPOS is an international study collecting data from 1,500 cancer patients who developed heart inflammation (myocarditis) after receiving immune checkpoint inhibitors. Researchers will analyze how different immunosuppressive treatments, such as steroids, affect survival rates at 30, 90, and 360 days. The goal is to identify which treatment strategies are linked to better outcomes, helping guide future care for this serious side effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED MYOCARDITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hopital Pitie-Salpetriere / CIC-2503
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could identify which immunosuppressive treatments are linked to better survival in patients with this rare heart condition caused by cancer immunotherapy.
What could go wrong
This is an observational study, not a controlled trial, so it can show associations but not prove cause and effect. Results may be affected by unmeasured factors or differences in patient care across countries.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.